VC
VRTX icon

Vestor Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Vestor Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90K Buy
202
+56
+38% +$26.1K 0.01% 202
2025
Q4 		$89K Sell
146
-200
-58% -$86.2K 0.01% 184
2025
Q3 		$136K Sell
346
-624
-64% -$261K 0.01% 178
2025
Q2 		$48K Buy
970
+624
+180% +$288K ﹤0.01% 259
2025
Q1 		$168K Sell
346
-9,390
-96% -$4.38M 0.01% 149
2024
Q4 		$3.92M Buy
9,736
+9,374
+2,590% +$4.35M 0.3% 68
2024
Q3 		$168K Buy
362
+51
+16% +$24.5K 0.01% 139
2024
Q2 		$146K Buy
311
+57
+22% +$24.7K 0.01% 149
2024
Q1 		$106K Sell
254
-2
-0.8% -$845 0.01% 180
2023
Q4 		$104K Buy
256
+25
+11% +$9.23K 0.01% 170
2023
Q3 		$80K Sell
231
-197
-46% -$68.9K 0.01% 182
2023
Q2 		$151K Buy
428
+235
+122% +$79.2K 0.02% 142
2023
Q1 		$61K Sell
193
-18
-9% -$5.4K 0.01% 205
2022
Q4 		$61K Buy
211
+53
+34% +$16.2K 0.01% 202
2022
Q3 		$46K Hold
158
– – 0.01% 204
2022
Q2 		$45K Hold
158
– – 0.01% 202
2022
Q1 		$41K Buy
+158
New +$37.5K ﹤0.01% 228
2021
Q4 		– Sell
-238
Closed -$43K – 247
2021
Q3 		$43K Buy
+238
New +$46.5K ﹤0.01% 228

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vestor Capital's VRTX Position: Q1 2026 in Review

Vestor Capital increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, buying an estimated $26.1K and bringing the position to 202 shares worth $90K. The position accounts for 0.01% of the portfolio, ranked #202.

Vestor Capital first reported a position in VRTX in Q3 2021 and has held it in 18 quarters since. The position peaked at $3.92M in Q4 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Vestor Capital held 202 shares of Vertex Pharmaceuticals worth $90K as of Q1 2026.
  • Vestor Capital bought 56 Vertex Pharmaceuticals shares in Q1 2026, an estimated $26.1K.
  • Vertex Pharmaceuticals made up 0.01% of Vestor Capital's portfolio in Q1 2026, its #202 holding.
  • Vestor Capital first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • Vestor Capital's Vertex Pharmaceuticals position peaked at $3.92M in Q4 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Vestor Capital's 13F filing for Q1 2026, filed 21 May 2026.